SCHEMBL4854942

SCHEMBL4854942

CCc1ccc(C(O)c2nccnc2Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
ATM Q13315 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
KMT2A Q03164 2/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
LMNA P02545 3/20 0.34
IDO1 P14902 1/20 0.34
TDO2 P48775 1/20 0.34
PRKDC P78527 2/20 0.33
KCNH2 Q12809 2/20 0.33
CHEK2 O96017 1/20 0.33
MEN1 O00255 1/20 0.33
CYP17A1 P05093 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2460557 0.78 LMNA (0.54) L3MBTL1LMNA
SCHEMBL5381416 0.77 MEN1 (0.53) L3MBTL1TSHRMAPK1ATMTDP1
SCHEMBL4854930 0.76 P4HB (0.39) L3MBTL1TSHRMAPK1ATMTDP1
SCHEMBL410107 0.72 SRD5A2 (0.49) TSHRKMT2ACYP2C19LMNAMEN1
SCHEMBL13772602 0.70 ACHE (0.40) ATMKMT2AMAPT
SCHEMBL3410613 0.69 SMN1; SMN2 (0.56) L3MBTL1TSHRLMNACYP17A1
SCHEMBL4857317 0.69 L3MBTL1 (0.39) L3MBTL1TSHRMAPK1ATMTDP1
SCHEMBL6899388 0.67 TP53 (0.54) L3MBTL1TSHRMAPK1ATMTDP1
SCHEMBL2464611 0.67 KCNH2 (0.36) NPC1LMNAIDO1TDO2PRKDC
SCHEMBL22497968 0.67 DYRK1A (0.31) L3MBTL1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7439232-B2 Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-10-21 US disclosed
US-20060194809-A1 Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same TAISHO PHARMACEUTICAL CO., LTD. (JP) 2006-08-31 US disclosed
CN-1761676-A Heteroaryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same TAISHO PHARMACEUTICAL CO LTD (JP) 2006-04-19 CN disclosed
EP-1609799-A1 HETEROARYL 5-THIO-BETA-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME TAISHO PHARMACEUTICAL CO., LTD (JP) 2005-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194809-A1 Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same SLC5A2, SLC5A1, UGGT1 L3MBTL1 3504/4885TSHR 3150/4885MAPK1 1569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.